While the substantial redundancy of mammalian APP family members3 indicates that therapeutic reduction in APP levels may be well tolerated, our findings suggest that the effects of removing or decreasing APP on TGFβ signaling and proteostasis should be monitored, and that the effects of reducing APP in the context of tauopathy should also be evaluated. This evidence concerns the gene TGFB1 and tauopathy.